Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass

Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer

“…Therefore, all the TRAP measured in this study was osteoclast-dependent. Although other biological markers of bone resorption are currently in fashion [3,22], TRAP meets more than enough criteria for considering it an adequate marker of bone resorption: 1) It correlates significantly and inversely with estrogen levels before and after Gn-RH agonist treatment [23], and in normal circumstances TRAP decreases with menarche and increases after menopause [24], 2) TRAP is elevated in diseases that are accompanied by a high remodeling rate [25], 3) TRAP correlates negatively with bone mass [23] and positively with alkaline phosphatase [26], as confirmed by this and other studies [23,26], 4) TRAP is sensitive to the effect of drugs that slow remodeling and reduce osteoclastic activity [27], 5) Osteoclastic TRAP is similar to serum TRAP 5b, as shown by electrophoretic mobility on acid gel [28], 6) Its specificity, because circulating TRAP 5b is exclusively osteoclastic in origin, increases its value as a marker of bone remodeling, 7) Finally, its determination in blood is easy [7] and free from the potential errors of markers quantitated in urine. Therefore, we do not think that more expensive markers, which require more complicated and sophisticated techniques, are necessary for evaluating bone resorption.…”

Calcium intake and bone mineral density: systematic review and meta-analysis

“… 7 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 Fifteen studied dietary sources of calcium (n=810 calcium, n=723 controls), 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 and 51 studied calcium supplements (n=6547 calcium, n=5710 controls). 7 12 13 14 ...…”

Mortality associated with hormone replacement therapy in younger and older women

“…Of these 370 studies, 30 met inclusion criteria (Table 1). 9,19–47 The κ score for interrater agreement in trial selection was 0.91 (95% CI, 0.82 to 1.00). Studies were excluded for the following reasons: 98 did not report any deaths, 110 provided data on patients already included in the analysis, 79 were of 6 months’ duration or less, 26 did not provide a control group, and 27 were not randomized.…”